

Laboratory Procedure Manual

Analyte: **Total Prostate-Specific Antigen (PSA)**

Matrix: **Serum**

Method: **Beckman Access**

Method No.:

Revised:

as performed by: *University of Washington Medical Center
Department of Laboratory Medicine
Immunology Division*

Contact: *Kathleen Hutchinson M.S., M.T. (ASCP) or
Mark Wener, M.D., Director*

Public Release Data Set Information

This document details the Lab Protocol for NHANES 2003–2004 data.

A tabular list of the released analytes follows:

Lab Number	Analyte	SAS Label (and SI units)
l11psa_c	LBXP1	PSA, total (ng/mL)

1. SUMMARY OF TEST PRINCIPLE AND CLINICAL RELEVANCE

The Access Hybritech PSA assay is a two-site immunoenzymatic "sandwich" assay. A sample is added to a reaction vessel with mouse monoclonal anti-PSA alkaline phosphatase conjugate and paramagnetic particles coated with a second mouse monoclonal anti-PSA antibody. The PSA in the sample binds to the immobilized monoclonal anti-PSA on the solid phase while, at the same time, the monoclonal anti-PSA conjugate reacts with a different antigenic site on the sample PSA. Separation in a magnetic field and washing removes material not bound to the solid phase. A chemiluminescent substrate, Lumi-Phos** 530 is added to the reaction vessel and light generated by the reaction is measured with a luminometer. The light production is proportional to the concentration of PSA in the sample. The amount of analyte in the sample is determined by means of a stored, multi-point calibration curve.

Prostate cancer is one of the most common types of cancer found in men, occurring in 50% of those over 70 years of age. As with other cancers, it may be more successfully treated if diagnosed early. In the past, digital rectal examination was the most accurate diagnostic modality for early stage prostate cancer, but the accuracy of the rectal examination has been shown to be limited. The protein prostate-specific antigen (PSA) has been more effective than other methods for monitoring diagnosed prostate cancer, and for finding new cases of prostate cancer. PSA is highly specific for prostatic tissue. Human prostate-specific antigen is a single chain glycoprotein with a molecular weight of approximately 34,000 Dalton, containing 7% carbohydrate by weight. Immunohistochemical studies have shown that PSA is confined to the cytoplasm of prostatic acinar cells and ductal epithelium. PSA is present in normal, benign hyperplastic, and malignant prostatic tissue, in metastatic prostatic carcinoma, and also in prostatic fluid and seminal plasma. PSA is not present in high concentrations in any other normal tissue obtained from men, although small amounts are produced by other tissues. It is not produced in large amounts by cancers of the breast, lung, colon, rectum, stomach, pancreas or thyroid, but small amounts may be produced in the setting of breast cancer, ovarian cancer, and colon cancer.

Elevated serum PSA concentrations have been reported in patients with prostate cancer, benign prostatic hypertrophy, or inflammatory conditions of other adjacent genitourinary tissues, but not in apparently healthy men, or men with non-prostatic carcinoma. Recently reported research indicates that PSA may serve as an accurate marker for assessing response to treatment in patients with stages B2 to D1 prostatic cancer. Serial measurement of PSA concentrations can be an important tool in monitoring patients with prostatic cancer and in determining the potential and actual effectiveness of surgery or other therapies.

Use of serum PSA for detection of prostate cancer in older men has been recommended by the American Cancer Society and the American Urological Society, but other professional organizations have questioned the wisdom of prostate cancer screening with PSA. In a series of men over age 50 screened with PSA measurement, approximately 35% with serum PSA in the range of 4.0 to 10.0 will be found to have prostate cancer, when sextant (6-sample) biopsies are performed.

2. SAFETY PRECAUTIONS

Consider all samples received for analysis potentially positive for infectious agents including HIV and the hepatitis B virus. Observe universal precautions. Wear gloves, lab coat, and safety glasses when handling all human blood products and infectious viruses. Place disposable plastic, glass, paper, and gloves that contact blood in a biohazard bag or discard pan to be autoclaved. Disinfect all work surfaces with staphene solution. Dispose of all biological samples and diluted specimens in a biohazard bag at the end of the analysis.

Do not pipette by mouth. Do not eat, drink or smoke in designated work areas. Wash hands thoroughly after removal or personal protective devices used in handling specimens and kit reagents.

Material safety data sheets for all reagents used in the performance of this assay, including but limited to staphene, and sodium azide are kept in the Immunology Division, University of Washington Medical Center (UWMC).

3. COMPUTERIZATION; DATA SYSTEM MANAGEMENT

- A. Each shipment of specimens received from the NHANES IV mobile unit arrives with a corresponding transmittal sheet and a Send File (a comma delineated text file) transmitted electronically (labeled *boxnum.shp*). This file contains the following information:

Send File

Field	Type
Sample ID	XXXXXXXXXX
Slot Number	XXX
Sample Collection Date	mm/dd/yyyy hh:mm:ss
MEC Comment Code	XX

- B. The information from the shipping file is imported into a result file with the following format:

Results File: PSA/free PSA-Vessel ID 75

Field	Format
Sample ID	XXXXXXXXXX
Slot Number	XXX
Sample Collection Date	mm/dd/yyyy hh:mm:ss
MEC Comment Code	XX
Date of Receipt	Mmddyyyy
PSA Total Date of Analysis	Mmddyyyy
PSA Total Analyst ID	XXX
PSA Total Run Number	{test code}mmddy.x(letter)
PSA Total (ng/mL)	XXXXX.X
PSA Total comment	XX
PSA Total 2.5% repeat (ng/mL)	XXXXX.X
PSA Free Date of Analysis	Mmddyyyy
PSA Free Analyst ID	XXX
PSA Free Run Number	{test code}mmddy.x(letter)
PSA Free (ng/mL)	XXXXX.XX
PSA Free comment	XX
PSA Free 2.5% repeat (ng/mL)	XXXXX.XX
PSA ratio (%)	XXX

- C. After the testing is completed, the run number, date of analysis, PSA result, PSA comment, PSA analyst, and the PSA 2.5% repeat results are entered into the result file.
- D. Data entry is checked for errors.

- E. After the free PSA testing has also been completed, resulted, and checked, the result file is transmitted electronically to NHANES WESTAT. Electronic and hard copies of the files are kept in the laboratory.
- F. Technical support for this system is provided by Westat, Rockville, MD (1-301-294-2036)

4. SPECIMEN COLLECTION, STORAGE, AND HANDLING PROCEDURES; CRITERIA FOR SPECIMEN REJECTION

- A. No special instructions such as fasting or special diets are required. Specimens for PSA testing should be drawn prior to prostatic manipulations such as digital rectal exams (DRE), prostatic massage, transrectal ultrasound, and prostatic biopsy. DRE may cause a transient increase in serum PSA levels. Transrectal needle biopsy has been shown to cause persisting PSA elevations. A 6-week waiting period between needle biopsy and PSA sampling is recommended.
- B. Serum is the required specimen type, plasma should not be used. If testing is to be done within 24 hours, samples can be refrigerated at 2–8°C. Freeze at –20°C or colder for longer storage.
- C. Blood should be collected aseptically and the serum separated by standard laboratory techniques. Specimens may be collected by using regular or serum-separator Vacutainers. Serum should be separated from the cells within 60 minutes of collection.
- D. The requested sample volume for the assay is 1.0 mL, and the minimum sample volume is 0.3 mL.
- E. Specimens may be stored in glass or plastic vials, as long as the vials are tightly sealed to prevent desiccation of the sample.
- F. Turbid samples or those with particulate matter should be centrifuged prior to assay.
- G. Repeated freeze-thaw cycles do not affect free PSA, total PSA, or percent free PSA, but prompt refreezing of the thawed samples is recommended.

5. PROCEDURES FOR MICROSCOPIC EXAMINATIONS; CRITERIA FOR REJECTION OF INADEQUATELY PREPARED SLIDES

Not applicable for this procedure.

6. PREPARATION OF REAGENTS, CALIBRATORS (STANDARDS), CONTROLS, AND ALL OTHER MATERIALS; EQUIPMENT AND INSTRUMENTATION

A. Instrumentation

- (1) Beckman Access or Access II Immunoassay System (Beckman Coulter, Fullerton, CA.)

The Beckman Access is a fully automated, random access, instrument that features on-board storage of reagent packs in a refrigerated compartment; an ultrasonic probe tip for level sense detection, sample and reagent delivery, mixing, and probe cleaning to minimize carryover; barcode identification of specimens and reagent packs; temperature controlled reaction reactions; and measurement and analysis of the light signal generated by the chemiluminescent reaction (RLU) using a weighted four parameter logistic curve math model.

The Hybritech Total PSA assay parameter settings for the instrument are as follows:

Parameter	Setting
Sample Volume Requirements	
Minimum sample volume	175 ul
Sample volume used for testing	25 ul
No. of Standard Points	6
Calibration curve calculation	Weighted 4-parameter logistic math model
Standard Curve Measuring Range	
(At initial dilution; approximate values, range is dependent upon standard value)	0.1 – 150.0 ng/mL

- (2) Hewlett Packard DeskJet printer (Hewlett Packard, Boise, ID)
- (3) Computers (Dell Computer Corporation, Round Rock, Texas).
- (4) Centrifuge (Jouan Inc., Winchester, VA)

B. Equipment

- (1) Reaction Vessels (Beckman Coulter, Fullerton, CA)
- (2) Sample Cups (Fisher Scientific, Pittsburgh, PA)
- (3) Latex gloves, disposable (Any manufacturer).
- (4) Pipettes and tips (Rainin, Emeryville, CA)

C. Reagents

All reagents are purchased from Beckman Coulter, Fullerton, CA.

- (1) R1: Access Hybritech PSA reagent packs:

Cat. No. 37200: 100 determinations, 50 tests/pack

Provided ready to use. Store upright and refrigerate packs at 2–10°C. Packs must be refrigerated at 2–10°C for a minimum of two hours before use on the instrument. Stable until the expiration date stated on the label when stored at 2–10°C. After initial use, the pack is stable at 2–10°C for 28 days. Signs of possible deterioration are a broken elastomeric layer on the pack or control values out of range.

R1a: Paramagnetic particles coated with mouse monoclonal anti-PSA suspended in Tris buffered saline with surfactant, bovine serum albumin (BSA), < 0.1% sodium azide, and 0.1% ProClin**300.

R1b: Mouse monoclonal anti-PSA alkaline phosphatase (bovine) conjugate diluted in phosphate buffered saline, with surfactant, BSA, protein (mouse), < 0.1% sodium azide and 0.25% ProClin**300.

- (2) Access Substrate Cat. No. 81906: 4 x 130 ml

Lumi-Phos* 530(buffered solution containing dioxetane. Lumigen* PPD, fluorescer, and surfactant.

Store at 2–8 °C. Stable until expiration date on label when unopened. Bring to room temperature (15–30 °C) at least 18 hours before use. Stable for 14 days at room temperature or after bottle has been opened.

- (3) Access Wash Buffer: Cat # 81907
Tris buffered saline, surfactant, <0.1% sodium azide, and 0.1% Pro Clin* 300. Provided ready to use. Store at room temperature (15–30 °C), stable until expiration date on label.
- (4) Hybritech PSA Sample Diluent: Cat # 37206
Buffered BSA, < 0.1% sodium azide, 0.5% ProClin**300. Provided ready to use. Allow the contents to stand for 10 minutes at room temperature and mix by gently inverting prior to use. Avoid bubble formation. Stable until the expiration date when stored at 2–8 °C.

D. Standards/Calibration Preparation

Access Hybritech PSA Calibrators Cat. No. 37205: 2.5 ml/vial

Provided ready to use. Store at 2 to 10°C. Mix contents by gently inverting before use. Avoid bubble formation. Stable until the expiration date stated on the vial labels when stored at 2–10°C. Control values out of range are a sign of possible deterioration.

- S0: Buffered BSA, < 0.1% sodium azide, 0.5% ProClin**300. Contains 0.0 ng/mL of PSA.
- S1, S2, S3, S4, S5: Human PSA at levels of approximately 0.5, 2.0, 10.0, 75.0, and 150 ng/mL, respectively, in buffered BSA, CQ. < 0.1% sodium azide, 0.5% ProClin**300. Refer to calibration card for exact concentrations.
- Calibration Card (with actual calibrator concentration information)


E. Preparation of Quality Control Materials

Three different levels of serum controls are run with each run. The controls are purchased from Medical Analysis Systems, Inc. (Camarillo, CA) or prepared in-house. The controls are stored frozen (–20°C or colder). Once thawed, the controls are stored at 2–8°C. The controls are stable until the expiration date on the label if frozen. Once thawed, they are stable for 30 days.

7. CALIBRATION AND CALIBRATION VERIFICATION PROCEDURES

A. Calibration Curve

Example PSA Calibration:



Test: PSA-Hyb

Cal Lot: 006541

Reagent Lot: 005711

Status: Accepted

Calibrated: 01-19-2001 08:47am
Curve Exp.: 02-16-2001 08:47 am

			Mean				
Stated Conc. ng/mL	RLU	RLU	1SD	% CV	Calc. Conc. ng/mL	Mean Calc. Conc. ng/mL	Flags
0.00	10799				0.00		
0.00	10540				No Value		
		10669	183	1.72		0.00	
0.48	93498				0.50		
0.48	93506				0.50		
		93502	6	0.01		0.50	
2.04	344334				1.99		
2.04	346291				2.01		
		345312	1384	0.40		2.00	
10.10	1668910				10.12		
10.10	1716080				10.41		
		1692495	33354	1.97		10.26	
74.70	10234400				74.40		
74.70	10242700				74.48		
		10238550	5869	0.06		74.44	
145.00	16999800				146.64		
145.00	17043200				147.20		
		17021500	30688	0.18		146.92	

PSA concentrations are calculated by using a calibration curve. This method utilizes a weighted four parameter standard curve with a direct relationship of measured light produced (RLU) to concentration of PSA protein in the serum sample. Serum results are expressed as ng/mL.

An active calibration curve is required for all tests. For the Access Hybritech PSA assay, calibration is required every 28 days or whenever new lot numbers of reagents are placed into use. Refer to the Operator's Guide and Reference Manual for complete instructions on calibration procedures.

B. Verification

- (1) Three levels of control are run for each test series. If, within a testing series, these controls do not conform to specifications as defined in the quality control manual, the entire series is invalidated.

8. PROCEDURE OPERATING INSTRUCTIONS; CALCULATIONS; INTERPRETATION OF RESULTS

A. Preliminaries

- (1) Bring all controls and patient specimens to room temperature before use. Mix any specimens or controls that have been frozen. Centrifuge samples with particulate matter prior to testing.
- (2) Prime system (pipettor, dispense, and substrate) 4 times.
- (3) Check reagent, substrate, wash buffer, and reaction vessel status. Load any needed supplies onto the instrument. Mix reagent pack contents by gently inverting pack several times before loading on the instrument. Do not invert open (punctured) packs. Mix reagents by swirling gently.

B. Instrument Operation (see operator's manual for details).

- (1) Gently mix, uncap and load specimens into specimen racks, with the barcode in the open slot. Make sure there are no bubbles. Alternately, use the barcode wand to identify the specimens, and then load samples into the appropriate sample cups. Load the racks onto the instrument.
- (2) Each day run a 1:100 dilution of a "pool" of patient specimens to check for high dose hook. The pool result should not be higher than the highest patient result. Refer all questions to a supervisor.
- (3) Select the PSA-Hyb test. Note: if free PSA is also ordered, this test can be run on the same aliquot. Testing is done in singlicate.
- (4) The instrument automatically calculates all results. After testing is completed, results are printed and review by the technologist. Samples with results > 150 ng/mL are diluted off-line and repeated; results are corrected for the dilution factor. Samples with results < 0.1 ng/mL are repeated to confirm. Do not rerun samples that have sat on the Access for more than 60 minutes. Pour fresh aliquots before rerunning.
- (5) Remove specimens and controls. Return controls to the refrigerator and refreeze specimens.
- (6) Perform scheduled instrument maintenance (daily, weekly, and monthly) as outlined on the maintenance log. See the operator's manual for specific instructions.

C. Recording of Data

- (1) Specimen results are entered into the assay specific results table created from the send file corresponding to the specific sample box using Excel software (Microsoft Corporation, Redmond WA). A copy of this table is printed out and checked for accuracy of data entry.
- (2) Control results are entered to the Assay Specific QC/Levey-Jennings Table using the Excel program. Compliance with the Westgard rules is evaluated. A copy of this table is printed out and checked for accuracy of data entry.

D. Replacement and Periodic Maintenance of Key Components

(1) Daily Maintenance:

Start-up:

- Inspect fluidics module.
- Check system supplies and replace as needed.
- Clean exterior of substrate, dispense, and aspirate probes.
- Prime pipettor, dispense, and substrate 4X.
- Verify temperature.

Shut-down:

- Check waste containers, empty if needed
- Perform special clean

(2) Weekly Maintenance:

- Change probes and clean them
- Clean exterior of the analyzer
- Clean upper portion of the main pipettor with alcohol wipe
- Inspect waste filter bottle for fluid
- Run system check

(3) Periodic Maintenance to be performed by the manufacturer's service engineer.

E. Calculations

Patient test results are determined automatically by the system software. The amount of analyte in a sample is determined from the measured light production by means of a stored nonlinear calibration curve. Patient test results can be reviewed using the Sample Results screen. Refer to the Operator's Guide for complete instructions on reviewing results.

9. REPORTABLE RANGE OF TEST RESULTS

Results are reported to the nearest tenth (0.1). The lowest reportable PSA result is 0.1 ng/mL. The assay does not have a maximum reportable limit since off-line dilutions can be made to bring the concentration within the working range of the assay. Estimates of imprecision can be generated from long-term quality control pool results.

10. QUALITY CONTROL (QC) PROCEDURES

- A. Bench quality controls are used in this analytical method. Bench quality control specimens are tested with each analytical run (a set of consecutive assays performed without interruption) so that judgements may be made on the day of analysis. The data from these materials are then used in estimating methodological imprecision and in assessing the magnitude of any time-associated trends.
- B. The bench controls are purchased in sufficient quantity to provide serum samples for all the assays for approximately 1 year. Ranges are established after 20 parallel runs with previously established controls. The quality control pools comprise three levels of concentration spanning the low, borderline and high ranges for PSA.
- C. Bench quality controls are placed at the beginning of each analytical run. After analysis, the long-term quality control charts (Levey-Jennings) for each control material are consulted to determine if the system is "in control." The Levey-Jennings chart plots the quality control material observations on the y axis and the date of the observation on the x axis. Quality control material observations are compared with the 95% and 99% confidence limits as well as with the center line (the overall mean of the characterization runs) prior to reporting any results. The system is out of control if any of the following events occur for any one of the quality control materials:
- The observation from a single pool falls outside the 99% confidence limits.
 - The observations from two pools fall either both above or both below the 95% confidence limits.
 - The observations from eight successive runs for one pool fall either all above or all below the center-line.

11. REMEDIAL ACTION IF CALIBRATION OR QC SYSTEMS FAIL TO MEET ACCEPTABLE CRITERIA

If the run is declared "out of control", the system (instrument, calibration standards, etc.) is investigated to determine the root of the problem before any results are released. Consult with the supervisor for

appropriate actions.

12. LIMITATIONS OF METHOD; INTERFERING SUBSTANCES AND CONDITIONS

- A. The upper reportable value is virtually unlimited. The upper limit for undiluted specimens is determined by the calibration material supplied by the manufacturer. Values exceeding this upper limit are repeated on dilution until values, prior to correction for dilution, fall between approximately 5.0–150.0 ng/mL
- B. The lowest reportable value is approximately 0.1 ng/mL. The lower limit of this assay's default dilution is determined by the calibration material supplied by the manufacturer. Values below this lower limit are repeated to confirm the result.
- C. PSA results should be interpreted in light of the total clinical presentation of the patient, including clinical history, data from additional tests and other appropriate information. The 5 alpha-reductase inhibitor drugs, e.g. finasteride, may affect PSA levels in some patients. Other drugs used to treat benign prostatic hyperplasia (BPH) may also affect PSA levels. Care should be taken in interpreting results from patients taking these drugs.
- D. This assay does not demonstrate "high dose hook" below 50,000 ng/mL.
- E. The following substances do not interfere with the assay:
 - Hemoglobin up to 500 mg/dL
 - Bilirubin up to 20 mg/dL
 - Triglycerides up to 1500 mg/dl
 - Total protein levels of 4.2–12.1 g/dL
 - Many different drugs, see the manufacturer's kit insert for a complete list and concentrations tested.
 - No significant interference was seen in recovery studies done with a specimen with a RF of 20,000 IU/mL, a specimen with a solid phase immune complex level of 73 AHG equiv./mL, a specimen with polyclonal gamma of 3.4 g/dL, or a specimen with an alkaline phosphatase over 1000 U/L.
- F. Human anti-mouse antibodies (HAMA) may be present in samples from patients who have received immunotherapy utilizing monoclonal antibodies. Additionally, other heterophile antibodies such as human anti-goat antibodies and human antibodies recognizing murine antibodies may be present in patient samples. This assay has been formulated to minimize the effects of these antibodies on the assay. However, results on patients that are known to have such antibodies should be interpreted carefully.
- G. **WARNING:** The concentrations of PSA in a given specimen determined with assays from different manufacturers can vary due to differences in assay methods and reagent specificity. Values obtained with different assay methods cannot be used interchangeably.

13. REFERENCE RANGES (NORMAL VALUES)
0–4.0 ng/mL

14. CRITICAL CALL RESULTS (PANIC VALUES)

Not applicable to this procedure.

15. SPECIMEN STORAGE AND HANDLING DURING TESTING

Specimens should be maintained at 20–25°C during testing. After testing, the samples are stored at –70°C or colder.

16. ALTERNATIVE METHODS FOR PERFORMING TEST OR STORING SPECIMENS IF TEST SYSTEM FAILS

There are no acceptable alternative methods of analysis. Specimens may be stored at 4–8°C for no longer than 8 days. Otherwise, specimens should be stored –70°C or colder until the system is returned to functionality.

17. TEST RESULT REPORTING SYSTEM; PROTOCOL FOR REPORTING CRITICAL CALLS (IF APPLICABLE)

Not applicable to this procedure.

18. TRANSFER OR REFERRAL OF SPECIMENS; PROCEDURES FOR SPECIMEN ACCOUNTABILITY AND TRACKING

Standard record keeping should be used for tracking specimens. The primary results include daily test results as well as stored quality control results.


The original NHANES IV ship file is copied into a template Excel file and onto the hard drive of a PC computer. After the results are entered into the database and assay results transmitted electronically, files are stored for 6 months on a server that is backed up on a daily basis. After 6 months, the result files are transferred onto a CD along copies of original ship files and QC information.

The residual serum is stored at $\leq -70^{\circ}\text{C}$ for 6 months after analysis, then it is returned to the NHANES Repository in Rockville, MD for long-term storage.

19. SUMMARY STATISTICS AND QC GRAPHS

Table 1. Summary Statistics for Total Prostate Specific Antigen by Lot

Summary Statistics for Total PSA by Lot						
Lot	N	Start Date	End Date	Mean	Standard Deviation	Coefficient of Variation
1/97	100	1/16/2003	2/2/2005	0.16	0.01	4.8
0305-2	22	1/16/2003	5/28/2003	10.51	0.31	2.9
0305-3	22	1/16/2003	5/28/2003	21.79	0.79	3.6
010TU	31	6/11/2003	2/25/2004	3.12	0.11	3.6
0508-2	78	6/11/2003	2/2/2005	21.61	0.60	2.8
0509-2	47	3/3/2004	2/2/2005	4.80	0.15	3.2



REFERENCES

1. Manufacturer Information:
 - a. Beckman Access Immunoassay System Operator's Guide and Reference Manual
 - b. Beckman Access Hybritech free PSA product insert #37210.
 - c. Beckman Access Hybritech free PSA Calibrators product insert #37215.
 - d. Beckman Access Substrate product insert #170279.
 - e. Beckman Access Wash Buffer product insert #170278.
2. Schacht, M.J., Garnett, J.E., and Grayhack, J. Biochemical Markers in Prostatic Cancer. Uro. Clin. No. Amer. 11:253, 1984.
3. Wang, M.C., Valenzuela, L.A., Murphy, G.P., and Chu, T.M. Purification of a Human Prostate Specific Antigen. Invest. Urol. 17:159, 1979.
4. Nadji, M., Tabei, S.Z., Castro, A., Chu, T.M., Murphy, G.P., Wang, M.C. and Morales, A.R. Prostatic-Specific Antigen: An Immunohistologic Marker for Prostatic Neoplasms. Cancer 48:1229, 1981.
5. Wang, M.C., Papsidero, L.D., Kuriyama, M., Valenzuela, L.A., Murphy, G.P., and Chu, T.M. Prostatic Antigen: A New Potential Marker for Prostatic Cancer. Prostate 2:89, 1981.
6. Frankel, A.E., Rouse, R.V., Wang, M.C., Chu, T.M. and Herzenberg, L.A. Monoclonal Antibodies to a Human Prostate Antigen. Cancer Res. 42:3714, 1982.
7. Papsidero, L.D., Wang, M.C., Valenzuela, L.A., Murphy, G.P., and Chu, T.M. A Prostate Antigen in Sera of Prostatic Cancer Patients. Cancer Res. 40:2428, 1980.
8. Kuriyama, M., Wang, M.C., Papsidero, L.D., Killian, C.S., Shimano, T., Valenzuela, L., Nishiura, T., Murphy, G.P. and Chu, T.M. Quantitation of Prostate-Specific Antigen in Serum by a Sensitive Enzyme Immunoassay. Cancer Res.
9. Killian, C.S., Yang, N., Emrich, L.J., Vargas, F.P., Kuriyama, M., Wang, M.C., Slack, N.H., Papsidero of Prostate-Specific Antigen for Monitoring Patients with Stages B2 to D1 Prostate Cancer. Cancer Res. 45:886, 1985.
10. Kuriyama, M., Wang, M.C., Lee, C.L., Killian, C.S., Papsidero, L.D., Inaji, H., Loo, R.M., Lin, M.F., Nishiura, T., Slack, N.H., Murphy, G.P., and Chu, T.M. Multiple Marker Evaluation in Human Prostate Cancer with the Use of Tissue-Specific Antigens. J. Nat. Canc. 68:99, 1982.
11. Woodrum, D., French, C., Shamel, L.B., Stability of Free Prostatic-Specific Antigen in Serum Samples Under a Variety of Sample Collection and Sample Storage Conditions. Urology 48(6a): 33-39, 1996.
12. Becker C, Noldus J, Diamandis E, Lilja H. The role of molecular forms of prostate-specific antigen (PSA or hK3) and of human glandular kallikrein 2 (hK2) in the diagnosis and monitoring of prostate cancer and in extra-prostatic disease. Crit Rev Clin Lab Sci. 2001 ;38(:357-99.
13. Neal D E, Donovan J L. Prostate cancer: to screen or not to screen? Lancet Oncol. 2000;1:17-24.
14. Canto EI, Slawin KM. Early management of prostate cancer: how to respond to an elevated PSA? Annu Rev Med. 2002;53:355-68.
15. Barry MJ. Clinical practice. Prostate-specific-antigen testing for early diagnosis of prostate cancer. N Engl J Med. 2001;344:1373-7.